Amendments to the Claims:

1. (original) A compound of Formula I

$$Y \longrightarrow N \longrightarrow R$$

Formula I

R is selected from the group consisting of OH, N_3 , -OR₁, -O-aryl, -O-heteroaryl, -OSO₂R₂, -NR₃R₄, and

wherein

- (i) R_1 is benzyl or C_{2-6} -acyl;
- (ii) R₂ is selected from the group consisting of phenyl, tolyl, and C₁₋₈-alkyl; and
- (iii) R₃ and R₄ are independently selected from the group consisting of hydrogen, C₃₋₆-cycloalkyl, phenyl, tert-butoxycarbonyl, fluorenyloxycarbonyl, benzyloxycarbonyl, -CO₂-R₅, -CO-SR₅, -CS-R₅, P(O)(OR₆)(OR₇), -SO₂-R₈ and C₁₋₆-alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of C₁₋₅-alkoxycarbonyl, OH, cyano, and halogen, wherein

 R_5 is selected from the group consisting of hydrogen, C_{3-6} -cycloalkyl, trifluoromethyl, phenyl, benzyl, and C_{1-6} -alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of C_{1-5} -alkoxycarbonyl, OH, cyano, halogen, and - NR_9R_{10} in which R_9 and R_{10} are independently selected from the group consisting of hydrogen, phenyl and C_{1-4} -alkyl;

 R_6 and R_7 are independently hydrogen or C_{1-4} -alkyl; and

 R_8 is phenyl or C_{1-4} -alkyl;

 R_{11} is selected from the group consisting of hydrogen, alkyl, -OR₁₃, -SR₁₃, amino, -NR₁₃R₁₄, aryl(C₁₋₈)alkyl, and mono-, di-, tri-, or per-halo C₁₋₈-alkyl;

 R_{12} is selected from the group consisting of CN, -COR₁₃, -COOR₁₃, -CO-NR₁₃R₁₄, -SO₂R₁₃, -SO₂-NR₁₃R₁₄, and nitro; and

 R_{13} and R_{14} are independently selected from the group consisting of hydrogen, alkyl, and aryl, or R_{13} and R_{14} taken together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group;

X is 0 to 4 members independently selected from the group consisting of halogen, OH, mercapto, nitro, halo- C_{1-8} -alkyl, C_{1-8} -alkoxy, C_{1-8} -alkylthio, C_{1-8} -alkyl-amino, di(C_{1-8} -alkyl)amino, formyl, carboxy, alkoxycarbonyl, C_{1-8} alkyl-CO-O-, C_{1-8} alkyl-CO-NH-, carboxamide, aryl, heteroaryl, CN, amino, C_{3-6} -cycloalkyl, C_{1-8} -alkyl optionally substituted with one or more members selected from the group consisting of F, Cl, OH, C_{1-8} alkoxy and C_{1-8} acyloxy; and

Y is a radical of Formula II:

Formula II

wherein

R₁₅, R₁₆, R₁₇, R₁₈, R₁₉, and R₂₀ are each independently selected from the group consisting of hydrogen, CN, nitro, C₁₋₈-alkyl, halo-C₁₋₈-alkyl, formyl, carboxy, alkoxycarbonyl,

carboxamide, aryl, and heteroaryl, or R_{15} and R_{16} and/or R_{17} and R_{18} and/or R_{19} and R_{20} together form an oxo group;

the moiety W represents any five- to ten-membered aromatic or heteroaromatic ring, said heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N;

Z is selected from the group consisting of hydrogen, halogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, CN, CHO, alkyl-CO-, alkoxy, $(C_{1-8}$ -alkyl)-CONH-, and $R_{21}R_{22}N$ -alkyl- wherein R_{21} and R_{22} are independently selected from the group consisting of hydrogen, C_{1-6} -alkyl, benzyl, aryl, and heteroaryl, or R_{21} and R_{22} together with the nitrogen to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group; and

m is 0 or 1

and the pharmaceutically acceptable salts and esters thereof.

- 2. (original) The compound of claim 1 wherein X is halogen.
- 3. (original) The compound of claim 1 wherein Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.
- 4. (original) The compound of claim 1 wherein the moiety W is a fused phenyl ring or a five- or six-membered heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N.
- 5. (original) The compound of claim 1 wherein Y is selected from the group consisting of

wherein

Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alkyl-CO-, and $R_{21}R_{22}N$ -alkyl- wherein R_{21} and R_{22} are independently selected from the group consisting of hydrogen, C_{1-6} -alkyl, benzyl, aryl, and heteroaryl, or R_{21} and R_{22} together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group.

- 6. (original) The compound of claim 5 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.
- 7. (original) The compound of claim 1 wherein R is selected from the group consisting of

8. (original) The compound of claim 6 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

9. (amended) A compound of Claim 1 having the formula:

10. (amended) A compound of Claim 1 having the formula:

11. A compound of Claim 1 having the formula:

12. (amended) A compound of Claim 1 having the formula:

13. (amended) A compound of Claim 1 having the formula:

14. (amended) A compound of Claim 1 having the formula:

15. (amended) A compound of Claim 1 having the formula:

16. (amended) A compound of Claim 1 having the formula:

17. (amended) A compound of Claim 1 having the formula:

18. (amended) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

19 and 20. (cancelled).

- 21. (amended) The method of Claim 19 or 20 A method of treating a subject having a condition wherein said condition is selected from the group consisting of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, bone and joint infections and hospital-acquired lung infections, said method comprising the step of administering to the subject a therapeutically effective amount of a compound according to claim 1.
- 22. (amended) The method of Claim 19 or 20 21 wherein said bacterium is selected from the group consisting of *S. aureus*, *S. epidermidis*, *S. pneumoniae*, *S. pyogenes*, *Enterococcus spp.*, *Moraxella catarrhalis* and *H. influenzae*.
- 23. (amended) The method of Claim 19 or 20 21 wherein said bacterium is a Gram-positive coccus.
- 24. (original) The method of Claim 23 wherein said Gram-positive coccus is drug-resistant.
- 25. (new) A method of preventing a subject from suffering from a condition selected from the group consisting of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, bone and joint infections and hospital-acquired lung infections, said method comprising the step of administering to the subject a prophylactically effective amount of a compound according to claim 1.
- 26. (new) The method of Claim 25 wherein said bacterium is selected from the group consisting of *S. aureus*, *S. epidermidis*, *S. pneumoniae*, *S. pyogenes*, *Enterococcus spp.*, *Moraxella catarrhalis* and *H. influenzae*.
- 27. (new) The method of Claim 25 wherein said bacterium is a Gram-positive coccus.
- 28. (new) The method of Claim 25 wherein said Gram-positive coccus is drug-resistant.